Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K

Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies

John Vizuete1, Alfredo Camero1, Mazyar Malakouti1

  • 1Department of Medicine, Division of Gastroenterology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.

Journal of Clinical and Translational Hepatology
|May 17, 2017
PubMed

Insights

Nonalcoholic fatty liver disease (NAFLD) is a growing health concern with limited treatments. Promising new drugs are in development, offering hope for better management of this condition.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is a significant global health issue.
  • Current pharmacologic treatments for NAFLD are limited.
  • The prevalence of NAFLD is increasing worldwide.

Purpose of the Study:

  • To review the pathophysiology and natural history of NAFLD.
  • To discuss diagnostic testing and current treatment strategies.
  • To highlight promising pharmacologic agents in development for NAFLD.

Main Methods:

  • Literature review of NAFLD pathophysiology and natural history.
  • Analysis of diagnostic testing modalities for NAFLD.
  • Evaluation of current and investigational pharmacologic therapies for NAFLD.

Main Results:

  • NAFLD encompasses a spectrum of liver conditions.
  • Diagnostic approaches include imaging and liver biopsy.
  • Several novel drug candidates targeting different pathways are in clinical trials.

Conclusions:

  • The development pipeline for NAFLD therapies is robust.
  • Clinicians will soon have expanded options for NAFLD management.
  • The future outlook for NAFLD patients and healthcare providers is optimistic.
Keywords:
Developmental drugsFatty liverHepatic steatosisNAFLNAFLDNASHNonalcoholic fatty liver diseaseSteatohepatitis

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

986

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
900
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.5K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
808
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
440